David Langenau, Ph.D.
Massachusetts General Hospital, USA
David Langenau is the Director of Molecular Pathology at the Massachusetts General Hospital in Boston, MA. He is an Associate Professor of Pathology at Harvard Medical School and Principal Investigator at the Harvard Stem Cell Institute. His research focuses on uncovering mechanisms that drive progression and relapse in pediatric tumors. Using novel, transgenic zebrafish models of pediatric sarcoma and leukemia that mimic human malignancy, his group has undertaken studies to discover novel therapies by addition of drugs to the water and imaging tumor growth in live zebrafish. Moreover, his group has utilized detailed imaging studies to visualize tumor cells in live animals and assess how cellular heterogeneity drives continued tumor growth. Capitalizing on insights gained from our zebrafish models of cancer, his findings are commonly extended to human disease.
Richard White MD, Ph.D.
Memorial Sloan Kettering Cancer Center
Richard White, M.D., Ph.D, is a physician-scientist interested in basic mechanisms underlying cancer evolution and metastasis. He clinically trained in Internal Medicine at Yale, followed by Medical Oncology training at the Dana Farber Cancer Institute and Massachusetts General Hospital. His postdoctoral work in Leonard Zon’s laboratory at Harvard Medical School contributed to the establishment of the zebrafish as a new model system in cancer. In his laboratory at Memorial Sloan Kettering Cancer Center, he is using the zebrafish to understand basic mechanisms of metastasis, the major cause of all cancer mortality. His lab focuses on three central components of tumor progression: 1) how do lineage identity programs in the cell of origin impact metastatic behavior, 2) how do cells in the tumor microenvironment (TME) promote or inhibit metastasis, and 3) how does the genome of the cancer cell evolve over time and space during metastasis? The zebrafish is a novel platform for addressing these questions because it allows for high-throughput, high-resolution in vivo imaging of cellular behavior, and is highly amenable to unbiased screening approaches. Prior work from his laboratory has demonstrated that fundamental mechanisms uncovered in zebrafish melanoma have direct applicability to the human disease. He ultimately aims to use the zebrafish to discover basic mechanisms of cancer cell metastasis in order to improve the management of patients with disseminated disease.
Vice President in waiting
Marina Mione, MD, Ph.D.
University of Trento
James Amatruda MD, PH.D.
Children’s Hospital of Los Angeles and University of Southern California
Liz Patton PH.D., MRC
MRC Human Genetics Unit, University of Edinburgh
Director of Emeritus
Graham Lieschke, M.B., B.S., B.Med.Sc., Ph.D., F.R.A.C.P.
Australian Regenerative Medicine Institute and Royal Melbourne Hospital
DIRECTOR OF EMERITUS
The Walter and Eliza Hall Institute of Medical Research